Shield managing director (MD) to retire
This article was originally published in Clinica
Shield Diagnostics managing director Gordon Hall has announced his retirement, to take place immediately. This comes at an awkward time for the UK company, which is in negotiations for a licensing agreement for its AFT heart attack prediction test. Shares in the company fell 100p to 617.5p on the news.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.